{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:48:50Z","timestamp":1782737330732,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00108-026-02139-9","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T14:56:05Z","timestamp":1781276165000},"page":"741-750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Psoriasisarthritis","Psoriatic arthritis"],"prefix":"10.1007","volume":"67","author":[{"given":"Michaela","family":"K\u00f6hm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Figat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Ninosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"10","key":"2139_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin\u00a0CT, Colbert\u00a0RA, Gladman\u00a0DD (2017) Psoriatic Arthritis. N Engl J Med 376(10):957\u2013970","journal-title":"N Engl J Med"},{"issue":"2","key":"2139_CR2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/annrheumdis-2012-201972","volume":"73","author":"E Theander","year":"2014","unstructured":"Theander\u00a0E, Husmark\u00a0T, Alenius\u00a0GM, Larsson\u00a0PT, Teleman\u00a0A, Geijer\u00a0M et\u00a0al (2014) Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5\u2011year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis 73(2):407\u2013413","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2139_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrrheum.2015.53","volume":"11","author":"E Lubberts","year":"2015","unstructured":"Lubberts\u00a0E (2015) The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol 11(7):415\u2013429","journal-title":"Nat Rev Rheumatol"},{"issue":"9999","key":"2139_CR4","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes\u00a0IB, Mease\u00a0PJ, Kirkham\u00a0B, Kavanaugh\u00a0A, Ritchlin\u00a0CT, Rahman\u00a0P et\u00a0al (2015) Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386(9999):1137\u20131146","journal-title":"Lancet"},{"issue":"8","key":"2139_CR5","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1002\/art.22758","volume":"56","author":"D McGonagle","year":"2007","unstructured":"McGonagle\u00a0D, Lories\u00a0RJ, Tan\u00a0AL, Benjamin\u00a0M (2007) The concept of a \u201csynovio-entheseal complex\u201d and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 56(8):2482\u20132491","journal-title":"Arthritis Rheum"},{"issue":"10136","key":"2139_CR6","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale\u00a0DJ, Fearon\u00a0U (2018) The pathogenesis of psoriatic arthritis. Lancet 391(10136):2273\u20132284","journal-title":"Lancet"},{"key":"2139_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1331217","volume":"15","author":"JG Krueger","year":"2024","unstructured":"Krueger\u00a0JG, Eyerich\u00a0K, Kuchroo\u00a0VK, Ritchlin\u00a0CT, Abreu\u00a0MT, Elloso\u00a0MM et\u00a0al (2024) IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol 15:1331217","journal-title":"Front Immunol"},{"issue":"3","key":"2139_CR8","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt\u00a0A, Chiricozzi\u00a0A (2018) The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol 55(3):379\u2013390","journal-title":"Clin Rev Allergy Immunol"},{"key":"2139_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1346757","volume":"11","author":"B Lob\u00e3o","year":"2024","unstructured":"Lob\u00e3o\u00a0B, Louren\u00e7o\u00a0D, Giga\u00a0A, Mendes-Bastos\u00a0P (2024) From PsO to PsA: the role of T(RM) and Tregs in psoriatic disease, a systematic review of the literature. Front Med (Lausanne) 11:1346757","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"2139_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40744-019-00185-4","volume":"7","author":"A Szentpetery","year":"2020","unstructured":"Szentpetery\u00a0A, Haroon\u00a0M, FitzGerald\u00a0O (2020) Cardiovascular Comorbidities in Psoriatic Disease. Rheumatol Ther 7(1):5\u201317","journal-title":"Rheumatol Ther"},{"issue":"1","key":"2139_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","volume":"3","author":"JM Moll","year":"1973","unstructured":"Moll\u00a0JM, Wright\u00a0V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3(1):55\u201378","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"2139_CR12","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates\u00a0LC, Soriano\u00a0ER, Corp\u00a0N, Bertheussen\u00a0H, Callis Duffin\u00a0K, Campanholo\u00a0CB et\u00a0al (2022) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 18(8):465\u2013479","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 2","key":"2139_CR13","doi-asserted-by":"publisher","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman\u00a0DD, Antoni\u00a0C, Mease\u00a0P, Clegg\u00a0DO, Nash\u00a0P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(Suppl 2):ii14\u2013ii17","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2139_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.semarthrit.2013.04.005","volume":"43","author":"LI Sakkas","year":"2013","unstructured":"Sakkas\u00a0LI, Alexiou\u00a0I, Simopoulou\u00a0T, Vlychou\u00a0M (2013) Enthesitis in psoriatic arthritis. Semin Arthritis Rheum 43(3):325\u2013334","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"2139_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001067","volume":"5","author":"A Zabotti","year":"2019","unstructured":"Zabotti\u00a0A, McGonagle\u00a0DG, Giovannini\u00a0I, Errichetti\u00a0E, Zuliani\u00a0F, Zanetti\u00a0A et\u00a0al (2019) Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia. RMD Open 5(2):e001067","journal-title":"RMD Open"},{"issue":"2","key":"2139_CR16","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/ard.2003.018184","volume":"64","author":"JE Brockbank","year":"2005","unstructured":"Brockbank\u00a0JE, Stein\u00a0M, Schentag\u00a0CT, Gladman\u00a0DD (2005) Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis 64(2):188\u2013190","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2139_CR17","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.semarthrit.2021.06.006","volume":"51","author":"D Poddubnyy","year":"2021","unstructured":"Poddubnyy\u00a0D, Jadon\u00a0DR, Van den Bosch\u00a0F, Mease\u00a0PJ, Gladman\u00a0DD (2021) Axial involvement in psoriatic arthritis: An update for rheumatologists. Semin Arthritis Rheum 51(4):880\u2013887","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"2139_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi\u00a0F, Calov\u00a0M, Kristensen\u00a0LE, Gladman\u00a0DD, Coates\u00a0LC, Jullien\u00a0D et\u00a0al (2019) Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J\u00a0Am Acad Dermatol 80(1):251\u2013265.e19","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2139_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/art.24172","volume":"61","author":"FC Wilson","year":"2009","unstructured":"Wilson\u00a0FC, Icen\u00a0M, Crowson\u00a0CS, McEvoy\u00a0MT, Gabriel\u00a0SE, Kremers\u00a0HM (2009) Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a\u00a0population-based study. Arthritis Rheum 61(2):233\u2013239","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2139_CR20","first-page":"438","volume":"50","author":"DR Jadon","year":"2023","unstructured":"Jadon\u00a0DR, Corp\u00a0N, van der Windt\u00a0DA, Coates\u00a0LC, Soriano\u00a0ER, Kavanaugh\u00a0A et\u00a0al (2023) Management of Concomitant Inflammatory Bowel Disease or Uveitis in Patients with Psoriatic Arthritis: An Updated Review Informing the 2021 GRAPPA Treatment Recommendations. J\u00a0Rheumatol 50(3):438\u2013450","journal-title":"J Rheumatol"},{"key":"2139_CR21","doi-asserted-by":"crossref","unstructured":"Kang JH, Coates LC. Therapeutic Windows Across the Psoriatic Arthritis Spectrum. Rheumatol Ther. 2025.","DOI":"10.1007\/s40744-025-00818-x"},{"key":"2139_CR22","doi-asserted-by":"crossref","unstructured":"Snoeck Henkemans SVJ, de Jong PHP, Luime JJ, Kok MR, Tchetverikov I, Korswagen LA, et\u00a0al. Window of opportunity in psoriatic arthritis: the earlier the better? RMD Open. 2024;10(1).","DOI":"10.1136\/rmdopen-2023-004062"},{"issue":"1","key":"2139_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1957-0","volume":"21","author":"E Kampylafka","year":"2019","unstructured":"Kampylafka\u00a0E, Simon\u00a0D, d\u2019 Oliveira\u00a0I, Linz\u00a0C, Lerchen\u00a0V, Englbrecht\u00a0M et\u00a0al (2019) Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study. Arthritis Res Ther 21(1):178","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"2139_CR24","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/ard-2023-224148","volume":"82","author":"A Zabotti","year":"2023","unstructured":"Zabotti\u00a0A, De Marco\u00a0G, Gossec\u00a0L, Baraliakos\u00a0X, Aletaha\u00a0D, Iagnocco\u00a0A et\u00a0al (2023) EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis 82(9):1162\u20131170","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2139_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/annrheumdis-2021-220865","volume":"81","author":"ML Acosta Felquer","year":"2022","unstructured":"Acosta Felquer\u00a0ML, LoGiudice\u00a0L, Galimberti\u00a0ML, Rosa\u00a0J, Mazzuoccolo\u00a0L, Soriano\u00a0ER (2022) Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheum Dis 81(1):74\u201379","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2139_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1136\/annrheumdis-2021-220761","volume":"81","author":"E Meer","year":"2022","unstructured":"Meer\u00a0E, Merola\u00a0JF, Fitzsimmons\u00a0R, Love\u00a0TJ, Wang\u00a0S, Shin\u00a0D et\u00a0al (2022) Does biologic therapy impact the development of PsA among patients with psoriasis? Ann Rheum Dis 81(1):80\u201386","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"2139_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-063650","volume":"12","author":"RH Haberman","year":"2022","unstructured":"Haberman\u00a0RH, MacFarlane\u00a0KA, Catron\u00a0S, Samuels\u00a0J, Blank\u00a0RB, Toprover\u00a0M et\u00a0al (2022) Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ Open 12(12):e063650","journal-title":"BMJ Open"},{"issue":"6","key":"2139_CR28","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","volume":"74","author":"M Haroon","year":"2015","unstructured":"Haroon\u00a0M, Gallagher\u00a0P, FitzGerald\u00a0O (2015) Diagnostic delay of more than 6\u00a0months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis 74(6):1045\u20131050","journal-title":"Ann Rheum Dis"},{"issue":"10230","key":"2139_CR29","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease\u00a0PJ, Rahman\u00a0P, Gottlieb\u00a0AB, Kollmeier\u00a0AP, Hsia\u00a0EC, Xu\u00a0XL et\u00a0al (2020) Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395(10230):1126\u20131136","journal-title":"Lancet"},{"issue":"4","key":"2139_CR30","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1016\/S2665-9913(22)00008-X","volume":"4","author":"LC Coates","year":"2022","unstructured":"Coates\u00a0LC, Tillett\u00a0W, D\u2019Agostino\u00a0MA, Rahman\u00a0P, Behrens\u00a0F, McDearmon-Blondell\u00a0EL et\u00a0al (2022) Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study. Lancet Rheumatol 4(4):e262\u2013e273","journal-title":"Lancet Rheumatol"},{"issue":"5 Suppl 93","key":"2139_CR31","first-page":"S82","volume":"33","author":"T Pincus","year":"2015","unstructured":"Pincus\u00a0T, Bergman\u00a0MJ, Yazici\u00a0Y (2015) Limitations of clinical trials in chronic diseases: is the efficacy of methotrexate (MTX) underestimated in polyarticular psoriatic arthritis on the basis of limitations of clinical trials more than on limitations of MTX, as was seen in rheumatoid arthritis? Clin Exp Rheumatol 33(5 Suppl 93):S82\u2013S93","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"2139_CR32","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/ard.2008.094946","volume":"68","author":"CT Ritchlin","year":"2009","unstructured":"Ritchlin\u00a0CT, Kavanaugh\u00a0A, Gladman\u00a0DD, Mease\u00a0PJ, Helliwell\u00a0P, Boehncke\u00a0WH et\u00a0al (2009) Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 68(9):1387\u20131394","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2139_CR33","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3899\/jrheum.180971","volume":"46","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde\u00a0D, Gladman\u00a0DD, FitzGerald\u00a0O, Kavanaugh\u00a0A, Graham\u00a0D, Wang\u00a0C et\u00a0al (2019) Radiographic Progression According to Baseline C\u2011reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. J\u00a0Rheumatol 46(9):1089\u20131096","journal-title":"J Rheumatol"},{"issue":"4","key":"2139_CR34","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg\u00a0SR, Bhatt\u00a0DL, Mikuls\u00a0TR, Koch\u00a0GG, Fleischmann\u00a0R, Rivas\u00a0JL et\u00a0al (2022) Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 386(4):316\u2013326","journal-title":"N Engl J Med"},{"issue":"6","key":"2139_CR35","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","volume":"81","author":"PJ Mease","year":"2022","unstructured":"Mease\u00a0PJ, Deodhar\u00a0AA, van der Heijde\u00a0D, Behrens\u00a0F, Kivitz\u00a0AJ, Neal\u00a0J et\u00a0al (2022) Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis 81(6):815\u2013822","journal-title":"Ann Rheum Dis"},{"key":"2139_CR36","doi-asserted-by":"crossref","unstructured":"Singla S, Ribeiro A, Torgutalp M, Mease PJ, Proft F. Difficult-to-treat psoriatic arthritis (D2T PsA): a\u00a0scoping literature review informing a\u00a0GRAPPA research project. RMD Open. 2024;10(1).","DOI":"10.1136\/rmdopen-2023-003809"},{"issue":"2","key":"2139_CR37","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/acr.22576","volume":"68","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh\u00a0A, van der Heijde\u00a0D, Beutler\u00a0A, Gladman\u00a0D, Mease\u00a0P, Krueger\u00a0GG et\u00a0al (2016) Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study. Arthritis Care Res (Hoboken) 68(2):267\u2013274","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"2139_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease\u00a0PJ, van der Heijde\u00a0D, Ritchlin\u00a0CT, Okada\u00a0M, Cuchacovich\u00a0RS, Shuler\u00a0CL et\u00a0al (2017) Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 76(1):79\u201387","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2139_CR39","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","volume":"81","author":"P Gisondi","year":"2022","unstructured":"Gisondi\u00a0P, Bellinato\u00a0F, Targher\u00a0G, Idolazzi\u00a0L, Girolomoni\u00a0G (2022) Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis 81(1):68\u201373","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2139_CR40","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/art.41652","volume":"73","author":"EF Leijten","year":"2021","unstructured":"Leijten\u00a0EF, van Kempen\u00a0TS, Olde Nordkamp\u00a0MA, Pouw\u00a0JN, Kleinrensink\u00a0NJ, Vincken\u00a0NL et\u00a0al (2021) Tissue-Resident Memory CD8+ T Cells From Skin Differentiate Psoriatic Arthritis From Psoriasis. Arthritis Rheumatol 73(7):1220\u20131232","journal-title":"Arthritis Rheumatol"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02139-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-026-02139-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02139-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:28:52Z","timestamp":1782736132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-026-02139-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2139"],"URL":"https:\/\/doi.org\/10.1007\/s00108-026-02139-9","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0K\u00f6hm ist als Referentin und Beraterin t\u00e4tig f\u00fcr: Johnson & Johnson, Lilly, BMS, AbbVie, Pfizer, Novartis, UCB, Amgen, Cellgen, AlfaSigma. F.\u00a0Behrens ist als Referent und Berater t\u00e4tig f\u00fcr: Johnson & Johnson, Lilly, BMS, AbbVie, Pfizer, Novartis, UCB, Amgen, Cellgen, AlfaSigma. M.\u00a0Figat und N.\u00a0Ninosu geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}